Featured 13F manager
Pfizer Inc.
New York, NY 4 processed 13Fs on this site · 2025 Q3–2026 Q2
- $170M
- 17 Positions
- 2026 Q2
- −28.9% QoQ
- Top 5 78.9%
Pfizer Inc. files a Form 13F. The latest book is 2026 Q2 at $170M, down 28.9% QoQ, led by Allogene Therapeutics, Celcuity, and Arvinas.
Portfolio
top 5 78.9% · top 10 95.7%
- ALLO - Allogene Therapeutics 27.6%
- CELC - Celcuity 17.3%
- ARVN - Arvinas 16.2%
- PYXS - Pyxis Oncology 11.4%
- WVE - Wave Life Sciences 6.4%
- BHVN - Biohaven 4.7%
- CRBU - Caribou Biosciences 4.6%
- Spero Therapeutics 3.1%
- ZNTL - Zentalis Pharmaceuticals 2.3%
- ORIC - Oric Pharmaceuticals 2.1%
- CRDF - Cardiff Oncology 1.8%
- ZURA - Zura Bio · CLASS A 1.7%
- Other 0.8%
AUM over time
Book
| ORIC - Oric Pharmaceuticals | 18.60% | Hold | 5,376,344 | $8.18 | $44M | — | — |
| ARVN - Arvinas | 17.34% | Hold | 3,457,815 | $11.86 | $41M | — | — |
| CELC - Celcuity | 14.74% | Hold | 349,406 | $99.74 | $35M | — | — |
| WVE - Wave Life Sciences | 13.48% | Hold | 1,875,000 | $17.00 | $32M | — | — |
| ALLO - Allogene Therapeutics | 12.76% | Hold | 22,032,040 | $1.37 | $30M | — | — |
| ZURA - Zura Bio · CLASS A | 6.58% | Hold | 2,970,022 | $5.24 | $16M | — | — |
| PYXS - Pyxis Oncology | 3.42% | Hold | 7,032,770 | $1.15 | $8M | — | — |
| CRBU - Caribou Biosciences | 3.15% | Hold | 4,690,431 | $1.59 | $7M | — | — |
| CRDF - Cardiff Oncology | 2.87% | Hold | 2,411,575 | $2.81 | $7M | — | — |
| BHVN - Biohaven | 2.41% | Hold | 505,645 | $11.29 | $6M | — | — |
| Spero Therapeutics | 2.33% | Hold | 2,362,348 | $2.33 | $6M | — | — |
| NXTC - Nextcure | 0.95% | Hold | 157,646 | $14.19 | $2M | — | — |
| ZNTL - Zentalis Pharmaceuticals | 0.54% | Hold | 953,834 | $1.35 | $1M | — | — |
| QTTB - Q32 Bio | 0.39% | Hold | 277,777 | $3.32 | $922K | — | — |
| ANTX - An2 Therapeutics | 0.34% | Hold | 715,295 | $1.14 | $815K | — | — |
| BOLT - Bolt Biotherapeutics | 0.07% | Hold | 31,305 | $5.47 | $171K | — | — |
| DNA - Ginkgo Bioworks · CL A | 0.01% | Hold | 2,928 | $8.31 | $24K | — | — |
| Senseonics | 0.01% | Reduce −95.0% | 2,171 | $5.52 | $12K | −41,255 | −$7K |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| BNTX - Biontech Se | 37.39% | Exit | 0 | $98.62 | $164M | −1,658,361 | −$164M |
| Tourmaline Bio | 13.91% | Exit | 0 | $47.83 | $61M | −1,272,214 | −$61M |
| Holding | 0.07% | Exit | 0 | $0.1910 | $320K | −1,675,000 | −$320K |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 17 | $170M | −28.9% | 13F-HR | 8/13/2026 | 000007800326000102 |
| 2026 Q1 | 18 | $239M | +1.3% | 13F-HR | 5/12/2026 | 000007800326000064 |
| 2025 Q4 | 18 | $236M | −46.0% | 13F-HR | 2/12/2026 | 000007800326000013 |
| 2025 Q3 | 21 | $437M | — | 13F-HR | 11/13/2025 | 000007800325000161 |
About
Pfizer Inc.
4 processed 13Fs on this site · 2025 Q3–2026 Q2